BERGEN, Norway, Nov. 7, 2019 /PRNewswire/ -- BerGenBio ASA
(OSE:BGBIO), will announce its results for the third quarter on
Tuesday 19 November 2019. A
presentation by BerGenBio's senior management team will take place
at 10am CET at:
Arctic Securities
Haakon VIIs gate 5
Oslo
The presentation will webcast live and the link will be
available at www.bergenbio.com in the section
Investors/Financial Reports. A recording will be available shortly
after the webcast has finished.
The results report and presentation will be available
at www.bergenbio.com in the section: Investors/Financial
Reports from 7:00 am CET the same
day.
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Nicholas
Brown, Lucy Featherstone,
Carina Jurs,
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux
Advisers
stiff@crux.no
+47 995 13 891
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad Phase II oncology
clinical development programme focused on combination and single
agent therapy in lung cancer and leukaemia. A first-in-class
functional blocking anti-AXL antibody is undergoing Phase I
clinical testing. In parallel, BerGenBio is developing a companion
diagnostic test to identify those patient populations most likely
to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in
Oxford, UK. The company is listed
on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-asa--invitation-to-third-quarter-2019-results-presentation-and-webcast,c2955673
The following files are available for download:
https://mb.cision.com/Main/15728/2955673/1137013.pdf
|
Release
|